| 词条 | Eyenovia |
| 释义 |
| name = Eyenovia Inc. | logo = File:Eyenovia Inc. Logo.jpg | logo_size = | logo_alt = | logo_caption = | image = | image_size = | image_alt = | image_caption = | trading_name = | native_name = | native_name_lang = | romanized_name = | former_name = PGP Holdings V Inc. | type = Public | traded_as = {{NASDAQ|EYEN}} | ISIN = US30234E1047 | ISIN2 = | industry = Pharmaceutical industry | genre = | fate = Active | predecessor = | successor = | founded = 5th May, 2014. | founder = | defunct = | hq_location = | hq_location_city = New York, New York | hq_location_country = United States of America | num_locations = | num_locations_year = | area_served = | key_people = | products = Micropine, Microprost, Microstat, Microtears. | brands = | production = | production_year = | services = | revenue = | revenue_year = | operating_income = | income_year = | net_income = | net_income_year = | aum = | assets = | assets_year = | equity = | equity_year = | owner = | members = | members_year = | num_employees = 11 | num_employees_year = November 28, 2018. | parent = | divisions = | subsid = | module = | ratio = | rating = | website = http://www.eyenoviabio.com/ | footnotes = }} Eyenovia inc. is a clinical stage ophthalmic biopharmaceutical company. It was formed in 2014 and has its headquarters in New York, New York in the United States. The company is focused on developing treatments for eye diseases. Eyenovia's four main products are Micropine for the treatment of myopia, Microprost for chronic angle closure glaucoma (CACG), Microstat to induce pupil dilation during eye examinations, and Microtears for dry eye. HistoryEyenovia was formed in 2014 [1] by Tsontcho (Sean) Ianchulev, MD, MPH to develop technology for updating the method in which eye drops are delivered. He had previously developed optical therapies for Genentech. The company filed for an IPO confidentially on November 15, 2017, on the NASDAQ.[2] It filed for 2,730,000 shares at $34,534,500 market capitalisation. The company went public on January 25, 2018. TechnologyMicro-dosingThe core of the company is its development of micro-dosing technology. Micro-dosing delivers a targeted dose of 5-9μL, which coats the surface of the cornea.[3] ProductsMicropine is the firm's lead program and its purpose is to prevent progressive myopia. As of November 2018, they are looking at studying in humans.[4] References1. ^https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=291491698L "Company Overview of Eyenovia, Inc" Retrieved 2018-11-20 2. ^https://www.nasdaq.com/article/eye-disease-biopharma-eyenovia-files-for-a-35-million-ipo-cm894282 "Eye disease biopharma Eyenovia files for a $35 million IPO". 2017-12-19. Retrieved 2018-11-20 3. ^{{cite journal |doi=10.2147/OPTH.S118409 |pmid=27994437 |pmc=5153265 |title=Systemic side effects of eye drops: A pharmacokinetic perspective |journal=Clinical Ophthalmology |volume=10 |pages=2433–2441 |year=2016 |last1=Farkouh |first1=Andre |last2=Frigo |first2=Peter |last3=Czejka |first3=Martin }} 4. ^{{cite journal |doi=10.1016/j.ophtha.2018.01.033 |pmid=29681290 |title=Public Health Burden and Potential Interventions for Myopia |journal=Ophthalmology |volume=125 |issue=5 |pages=628–630 |year=2018 |last1=Modjtahedi |first1=Bobeck S. |last2=Ferris |first2=Frederick L. |last3=Hunter |first3=David G. |last4=Fong |first4=Donald S. }} 3 : Pharmaceutical companies of the United States|2014 establishments in the United States|Companies listed on NASDAQ |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。